San Diego, CA – June 7, 2016- Regen BioPharma, Inc. (OTCQB: RGBP), (OTCQB: RGBPP), announced today that it has retained Objective Capital Partners, LLC as its advisor to assist the company in exploring strategic partnerships, co-development and licensing agreements to enhance shareholder value and provide a source of non-dilutive funding. The strategies being explored include partnering assets of the Company with the goal to provide a source of non-dilutive funding to primarily support Regen’s NR2F6, tCellVax and small molecule programs.
Co-development and partnership relationships to be major focus of funding arrangements
“We have several material assets whose monetization in the near term can support the growth needs of our NR2F6 programs. Our most advanced therapeutic asset, HemaXellerate, may be of particular interest to strategic partners interested in rare diseases as it is FDA-cleared for testing in aplastic anemia patients,” said David Koos, Ph.D., Chief Executive Officer. “Among our programs, the NR2F6 program has by far the most potential value to patients and our shareholders. We need to make sure we have the financing in place to execute on management’s plan to advance the NR2F6 program to the point where Big Pharma will be interested in this asset.”
Regen BioPharma’s pipeline includes autologous cell therapies (HemaXellerate, dCellVax, tCellVax), universal donor cell therapy (ucVax) and small molecules (NR2F6 program). HemaXellerate is the subject of an FDA-cleared IND and Phase I/II clinical trial that is intended to determine safety and potential efficacy of intravenously administered autologous stromal vascular fraction (SVF) cells in patients with severe, immune suppressive refractory aplastic anemia. The Company also intends to amend its IND and pursue a Phase I/II clinical trial assessing HemaXellerate in patients suffering from chemotherapy-induced bone marrow suppression. As reported previously, HemaXellerate is being tested at the Pan Am Cancer Treatment Center in Mexico in a first-in-human proof of concept study in patients with chemotherapy-induced bone marrow suppression. Additionally, both dCellVax and tCellVax have IND’s under review by the FDA for the treatment of breast cancer and solid tumors, respectively.
“With 22 patents pending or issued, we need to carefully calibrate our prioritization of funds to ensure that we maximize patient benefit and shareholder value,” said Harry Lander, Ph.D., MBA, President and Chief Scientific Officer. “A source of non-dilutive funding would be very welcome and would allow us to greatly advance our NR2F6 program while at the same time continue to advance some of our other assets such as dCellVax and tCellVax.”
“We are an ideal advisor on this strategic engagement given our domain expertise and experience in executing sell-side and licensing transactions in the space,” stated David H. Crean, Ph.D., Managing Partner for the Healthcare and Life Science practice at Objective Capital Partners. “There are numerous examples of precedent collaborative partnering transactions that have occurred over the past few years between biotechnology and pharmaceutical companies involving autologous cell therapies. We are excited to partner with Regen’s management and explore the likelihood of completing asset transactions with strategic targets in order to achieve our client’s objectives.”
About Regen BioPharma Inc.:
Regen BioPharma Inc. is a publicly traded biotechnology company (OTCQB: RGBP and (OTCQB: RGBPP). The Company seeks to identify undervalued regenerative medicine applications in the immunotherapy and stem cell space. The Company is focused on rapidly advancing these technologies through pre-clinical and Phase I/ II clinical trials. Currently the Company is focused on gene silencing therapy and small molecule therapies for treating cancer, along with developing stem cell treatments for aplastic anemia and disorders of the bone marrow. Additional information on Regen Biopharma is available at http://www.regenbiopharmainc.com.
About Objective Capital Partners, LLC:
Objective Capital Partners is a leading M&A investment banking firm whose Principals have collectively engaged in more than 500 successful transactions serving the transaction needs of growth stage and mid-size companies. The executive team has a unique combination of investment banking, private equity, and business ownership experience that enables Objective Capital Partners to provide large enterprise caliber investment banking services to companies with annual revenues up to $500 million. Services include sale transactions, equity and debt capital raises and comprehensive advisory services. The firm uses a proprietary process to work to achieve maximum company valuation, premium pricing, and high client satisfaction rates post-sale. The firm’s industry expertise includes: life sciences, business services, software and hardware technology, aerospace/defense, IT services, healthcare services, energy services, biotech, consumer products and specialized manufacturing. Securities and investment banking services are offered through BA Securities, LLC Member FINRA, SIPC. The Principals of Objective Capital Partners are Registered Representatives of BA Securities. Objective Capital Partners and BA Securities are separate and unaffiliated entities. Additional information on Objective Capital Partners is available at www.objectiveibv.com.
Disclaimer: This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
Regen BioPharma Inc.
David R. Koos, Ph.D.
Chairman & Chief Executive Officer
Objective Capital Partner inquiries:
This news release is for informational purposes only and does not constitute an offer, invitation or recommendation to buy, sell, subscribe for or issue any securities. While the information provided herein is believed to be accurate and reliable, Objective Capital Partners and BA Securities, LLC make no representations or warranties, expressed or implied, as to the accuracy or completeness of such information. All information contained herein is preliminary, limited and subject to completion, correction or amendment. It should not be construed as investment, legal, or tax advice and may not be reproduced or distributed to any person.